JP Morgan Chase’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-288,970
| Closed | -$13.7M | – | 7397 |
|
|
2025
Q3 | $13.7M | Sell |
288,970
-24,523
| -8% | -$1.19M | ﹤0.01% | 2447 |
|
|
2025
Q2 | $16.7M | Sell |
313,493
-18,890
| -6% | -$858K | ﹤0.01% | 2092 |
|
|
2025
Q1 | $13.5M | Sell |
332,383
-195,824
| -37% | -$8.3M | ﹤0.01% | 2281 |
|
|
2024
Q4 | $14.7M | Buy |
528,207
+40,161
| +8% | +$1.22M | ﹤0.01% | 2332 |
|
|
2024
Q3 | $14M | Sell |
488,046
-54,221
| -10% | -$1.41M | ﹤0.01% | 2312 |
|
|
2024
Q2 | $12.7M | Buy |
542,267
+216,868
| +67% | +$4.64M | ﹤0.01% | 2242 |
|
|
2024
Q1 | $8.22M | Buy |
325,399
+172,521
| +113% | +$4.14M | ﹤0.01% | 2663 |
|
|
2023
Q4 | $3.57M | Sell |
152,878
-561,700
| -79% | -$11.1M | ﹤0.01% | 3388 |
|
|
2023
Q3 | $36.1M | Buy |
714,578
+377,258
| +112% | +$17.6M | ﹤0.01% | 1276 |
|
|
2023
Q2 | $15.7M | Buy |
337,320
+125,852
| +60% | +$5.77M | ﹤0.01% | 1886 |
|
|
2023
Q1 | $8.09M | Buy |
211,468
+28,153
| +15% | +$1.26M | ﹤0.01% | 2460 |
|
|
2022
Q4 | $10M | Sell |
183,315
-52,214
| -22% | -$2.24M | ﹤0.01% | 2247 |
|
|
2022
Q3 | $8.02M | Buy |
235,529
+702
| +0.3% | +$10.7K | ﹤0.01% | 2337 |
|
|
2022
Q2 | $2.22M | Buy |
234,827
+188,960
| +412% | +$1.97M | ﹤0.01% | 3454 |
|
|
2022
Q1 | $651K | Sell |
45,867
-1,957
| -4% | -$34.3K | ﹤0.01% | 4531 |
|
|
2021
Q4 | $1.01M | Sell |
47,824
-1,006
| -2% | -$22.3K | ﹤0.01% | 4372 |
|
|
2021
Q3 | $1.09M | Sell |
48,830
-2,139
| -4% | -$48.4K | ﹤0.01% | 4246 |
|
|
2021
Q2 | $1.26M | Buy |
50,969
+2,933
| +6% | +$82.4K | ﹤0.01% | 4130 |
|
|
2021
Q1 | $1.39M | Buy |
48,036
+1,491
| +3% | +$45.1K | ﹤0.01% | 3974 |
|
|
2020
Q4 | $1.2M | Sell |
46,545
-11,639
| -20% | -$324K | ﹤0.01% | 3840 |
|
|
2020
Q3 | $1.83M | Sell |
58,184
-5,237
| -8% | -$183K | ﹤0.01% | 3295 |
|
|
2020
Q2 | $1.58M | Buy |
63,421
+12,172
| +24% | +$278K | ﹤0.01% | 3257 |
|
|
2020
Q1 | $1.09M | Sell |
51,249
-54,481
| -52% | -$1.17M | ﹤0.01% | 3344 |
|
|
2019
Q4 | $2.35M | Buy |
105,730
+21,763
| +26% | +$450K | ﹤0.01% | 3273 |
|
|
2019
Q3 | $1.91M | Buy |
+83,967
| New | +$1.95M | ﹤0.01% | 3449 |
|
Other funds holding AKRO
JP Morgan Chase's AKRO Position: Q4 2025 in Review
JP Morgan Chase sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 288,970 shares — an estimated $13.7M sold.
JP Morgan Chase first reported a position in AKRO in Q3 2019 and held it in 25 quarters. The position peaked at $36.1M in Q3 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- JP Morgan Chase reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- JP Morgan Chase sold 288,970 Akero Therapeutics shares in Q4 2025, an estimated $13.7M.
- JP Morgan Chase first reported a position in Akero Therapeutics in Q3 2019 and held it in 25 quarters.
- JP Morgan Chase's Akero Therapeutics position peaked at $36.1M in Q3 2023.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.